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Summary 
Incidence of bloodstream infections in Malawian children declined significantly over two decades, but 
resistance of Gram-negative pathogens to empiric first-line antimicrobials increased from 3.4% to 30.2% 
for children ≤5 years and 7.0% to 67.7% for young infants ≤60 days.  
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Abstract 
Background: The adequacy of the WHO Integrated Management of Childhood Illness (IMCI) 
antimicrobial guidelines for the treatment of suspected severe bacterial infections is dependent on a low 
prevalence of antimicrobial resistance (AMR). We describe trends in etiologies and susceptibility patterns 
of bloodstream infections (BSI) in hospitalized children in Malawi. 
 
Methods: We determined the change in population-based incidence of BSI in children admitted to Queen 
Elizabeth Central Hospital, Blantyre, Malawi (1998-2017). AMR profiles were assessed by the disc 
diffusion method and trends over time were evaluated.  
 
Results: A total 89,643 pediatric blood cultures were performed, and 10,621 pathogens were included in 
the analysis. Estimated minimum incidence rates of BSI for those ≤5 years of age fell from a peak of 11.4 
per 1,000 persons in 2002 to 3.4 per 1,000 persons in 2017. Over two decades, resistance of Gram-
negative pathogens to all empiric first-line antimicrobials (ampicillin/penicillin, gentamicin, ceftriaxone) 
among children ≤5 years increased from 3.4% to 30.2% (p<0.001). Among those ≤60 days, AMR to all 
first-line antimicrobials increased from 7.0% to 67.7% (p<0.001). Among children ≤5 years, Klebsiella 
spp. resistance to all first-line antimicrobial regimens increased from 5.9% to 93.7% (p<0.001).  
 
Conclusions: The incidence of BSI among hospitalized children has decreased substantially over the last 
20 years, although gains have been offset by increases in Gram-negative pathogens resistant to all empiric 
first-line antimicrobials. There is an urgent need to address the broader challenge of adapting IMCI 
guidelines to the local setting in the face of rapidly expanding AMR in childhood BSI.  
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Sepsis accounted for half a million child deaths globally in 2000, and had the lowest decline of all the top 
seven causes of death in this population by 2015, with only a 25% decrease compared to other leading 
causes such as pneumonia (47%), diarrhea (57%) and measles (85%) [1]. In 2015, sepsis and other 
infectious conditions of the newborn accounted for 7% of all deaths worldwide among children under 5 
years of age [1]. Empiric first-line antimicrobial treatment for sick infants in the World Health 
Organization (WHO) Integrated Management of Childhood Illness (IMCI) guidelines consists of 
penicillin/ampicillin with gentamicin, or ceftriaxone (as is practiced in Malawi). At our center in Malawi, 
ceftriaxone has been available since 2001, was introduced as an empiric antibiotic for neonatal meningitis 
in 2009 [2], and has been used as first-line treatment for suspected neonatal sepsis since 2013 [3]. 
Pediatric departmental guidelines recommend use of penicillin and gentamicin for suspected sepsis, or 
ceftriaxone for suspected meningitis, typhoid fever and non-typhoidal Salmonella (NTS). These 
recommendations are based on sparse data from low- and middle-income countries (LMICs), and are 
intended to be adjusted to local susceptibility patterns so that ‘appropriate therapy [can be given] for an 
identified bacterial cause’ [4]. This can be challenging in LMICs, where paucity of diagnostic 
microbiology facilities [5] limits the ability of clinicians to optimize empiric therapy.  
 
Child mortality in Malawi has been falling in the last 20 years as a consequence of multiple interventions 
including better nutrition, new vaccines (H. influenzae type b conjugate vaccine in 2002, and S. 
pneumoniae conjugate vaccine in 2011), rapid roll-out of HIV prevention and care and improvements in 
malaria control [6-11]. A growing problem has been increasing rates of antimicrobial resistance (AMR) 
[12, 13], which may be caused and compounded by inappropriate prescribing, under-dosing, and 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy834/5113431 by U
niversity of Liverpool user on 11 O
ctober 2018
  7 
nonadherence to guidelines [14, 15]. There is a scarcity of high quality bloodstream infection (BSI) 
surveillance data to inform policy change. We have previously documented the expansion of extended-
spectrum beta-lactamase (ESBL) and fluoroquinolone resistance among common Gram-negative 
pathogens, as well as the emergence of methicillin-resistant Staphylococcus aureus (MRSA) in BSI [12], 
but did not explore this in detail in the population ≤5 years where the impact may be greatest. This study 
reviews the pediatric surveillance data collected over two decades at an urban district hospital and tertiary 
referral center in Malawi. We describe trends in the etiology and the prevalence of AMR amongst BSI 
isolates cultured from hospitalized children. Finally, we assess the adequacy of current IMCI guidelines in 
this setting. 
 
Methods 
 
Setting 
Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi, is a 1,250 bed government-funded 
teaching hospital providing free medical care and is the main teaching hospital of the University of 
Malawi College of Medicine. It is the referral center for the southern half of the country and serves as the 
district hospital for the urban Blantyre area (estimated population 920,000 in 2016). The pediatric 
department admits 20,000-30,000 children a year, with 65,000-80,000 seen annually in the pediatric 
Accident and Emergency unit. Total numbers of pediatric hospital admissions have remained broadly 
constant over the study period (Supplementary Table 1). Similarly, the neonatal unit admits 3,500 
neonates a year, and these numbers have remained consistent over the past decade, when admission data 
were first collected.  
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Study design 
We reviewed blood culture data collected at QECH over 20 consecutive years (1998-2017; 
Supplementary Figure 1). Blood culture sampling in children was obtained from any pediatric patient 
with: clinical suspicion of sepsis, severe sepsis or septic shock [16]; non-focal febrile illness who tested 
negative for malaria, or who remained febrile despite empiric antimicrobial treatment. Sampling followed 
set departmental guidelines which have remained unchanged over the period of surveillance. Repeat 
blood cultures were not routinely done in the setting of a positive result. Precise individual or population-
based antimicrobial usage data for the surveillance period were not available. Analysis of microbiological 
surveillance data was approved by the University of Malawi College of Medicine Research Ethics 
Committee (COMREC, P.08/14/1614).  
 
Microbiology 
Routine, quality-assured, diagnostic blood culture service has been provided for children admitted to 
QECH by the Malawi-Liverpool-Wellcome Trust Clinical Research Programme since 1998. Among 
children, 1-2 mLs of blood were obtained where possible for culture under aseptic conditions and 
inoculated into a single aerobic bottle (BacT/Alert, bioMérieux, Marcy-L’Etoile, France). All lab data 
over the study period were collected for children ≤5 years, including young infants <60 days. Further 
clinical data was unavailable. Where possible, all duplicates were removed. 
 
The automated BacT/Alert system (bioMérieux, France) has been used to incubate samples since 2000. 
Before then, manual culture was used as previously described [17] with organism identification using 
APIs (Biomérieux). Staphylococci were identified by slide coagulase, beta-hemolytic Streptococci by 
Lancefield antigen testing and Salmonellae by serotyping according to the White-Kauffmann-Le Minor 
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scheme. Haemophilus influenzae were typed using type b antisera. Aerococcus spp., Alcaligenes spp., 
alpha-hemolytic streptococci (other than S. pneumoniae), Bacillus spp., Corynebacteria, Micrococcus 
spp., coagulase negative staphylococci, unidentified gram-positive rods, and Rhizobium spp. that form 
part of the normal skin or oral flora, were considered contaminants.  
 
In Malawi, first-line antimicrobial regimens for treatment of pediatric and neonatal BSI include 
ampicillin/penicillin with gentamicin, or ceftriaxone. Antimicrobial susceptibility was determined by the 
disc diffusion method (Oxoid, United Kingdom) following the current version of the British Society of 
Antimicrobial Chemotherapy guidelines (BSAC, http://www.bsac.org.uk). Intermediate susceptibility 
(with the exception of S. pneumoniae) was regarded as resistant. Methicillin resistance in S. aureus was 
inferred by resistance to cefoxitin, which replaced oxacillin resistance testing in 2010. For S. pneumoniae, 
reduced susceptibility to penicillin was detected by oxacillin disc, with resistance defined as MIC >2 
µg/mL. Formal MIC testing was not done. Since 2007, gram-negative isolates have been screened for 
ESBL-producing status using a cefpodoxime disc. Prior to this, ESBL-producing status was inferred 
based on resistance to ceftriaxone.  
 
Statistical analysis 
We estimated minimum annual incidence rates, expressed as incidence per 1,000 age-specific person 
years, by dividing the number of bacteremia cases per year by mid-year population and multiplying by 
1,000. We modeled the observed annual case frequencies and then estimated incidence by dividing the 
predicted case frequencies by the mid-year populations. Age-stratified population estimates for urban 
Blantyre for the years 1998-2017 were obtained from the 1998 and 2008 National Population Projections 
by the National Statistical Office (NSO, http://www.nsomalawi.mw). We used yearly values for children 
≤5 years, but when there were low numbers of cases including for young infants ≤60 days, we combined 
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data into 5-year periods to enable comparisons. We followed the WHO definition of young infants as ≤60 
days [4] and defined early-onset neonatal BSI as <7 days and late-onset neonatal BSI as 7-90 days. We 
used negative binomial regression models to test for linear trend in incidence and the Cochran-Armitage 
test to detect trends in AMR rates. All statistical analyses were performed using R Statistical Package 
version 3.3.2 for MacOS (R Core Team, http://www.r-project.org).  
 
Results 
Between 1998-2017, a total of 89,643 blood cultures from pediatric patients were identified. Of these, 
10,621 pathogenic bacteria were identified from children ≤5 years, including 2,898 from young infants 
≤60 days.  
 
Incidence rates 
Minimum incidence rates of pediatric BSI decreased significantly over two decades (Figure 1), falling 
from a peak of 11.4 per 1,000 persons in 2002 for children ≤5 years to 3.4 per 1,000 persons in 2017 
(overall decreasing trend, p<0.001). For young infants, minimum incidence rates decreased from 8.7 per 
1,000 persons in 2000 to 1.7 per 1,000 persons in 2008 with an overall decreasing trend of incidence 
(p=0.05). However, since 2008, minimum incidence rates for young infants have been rising, with a steep 
rise from 2.8 per 1,000 persons in 2015 to 6.3 per 1,000 persons in 2017. For most pathogens there is an 
overall decreasing trend in minimum incidence rates (Figures 1B-F) over the two decades, with the 
exception of Salmonella Typhi and Klebsiella spp. For S. Typhi, minimum incidence rates for children ≤5 
years increased from a low of 0 per 1,000 persons in 2003 to a peak of 1.3 per 1,000 persons in 2013, and 
then declined to 0.3 per 1,000 persons in 2017 (overall increasing trend, p=0.0016); for Klebsiella spp., 
minimum incidence rates increased from a low of 0.2 per 1,000 persons in 2012 to 0.9 per 1,000 persons 
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in 2017 (p=0.727). However, when the outlier values for 2016 and 2017 were excluded, there was a 
declining trend for Klebsiella spp. sepsis between 1998 and 2015. (p=0.009) 
 
Pathogen etiology 
During the first period (1998-2002; Table 1), NTS accounted for 41.4% (1,644/3,964) of pathogenic 
isolates, followed by S. pneumoniae at 10.2% (405/3,964), and S. aureus and E. coli at 6.2% each 
(247/3,964). In the last period (2013-2017), the most common causes of pediatric BSI were Salmonella 
Typhi (544/2,614, 20.8%), Klebsiella spp. (316/2,614, 12.1%, with K. pneumoniae comprising 93.7% 
(295) of these), NTS (303/2,614, 11.6%), and Staphylococcus aureus (253/2,614, 9.7%). S. pneumoniae 
accounted for 1.9% (49/2,614) of isolates in the last period. For young infant BSI in the first period 
(Supplementary Table 2), the most common causes were NTS (133/835, 15.9%), S. aureus (118/835, 
14.1%), and Group B Strep (GBS, 109/835, 13.1%). In the last period, the most common causes were 
Klebsiella spp. (230/800, 28.9%), followed by S. aureus (139/800, 17.4%), Enterobacter spp. (101/800, 
12.6%), Enterococcus spp. (72/800, 9%), E. coli (57/800, 7.1%) and GBS (43/800, 5.4%). Only 0.6% 
(5/800) of S. pneumoniae specimens were isolated from young infants in the last period compared to 6.2% 
(52/835) in the first.  
 
AMR profiles 
For Gram-positive pathogens, resistance to empiric first-line antimicrobials (ampicillin/penicillin with 
gentamicin, or ceftriaxone) was 21.1% (605/2,863) and 6.2% (74/1,199) of isolates, respectively. For 
Gram-negative pathogens, the proportion of culture-confirmed BSI among children ≤5 years that were 
resistant to all first-line antimicrobials had an overall increasing trend over time, from 3.4% (8/235) in the 
first period to 30.2% (449/1,487) in the last period (p<0.001; Figure 2). For young infants, the overall 
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proportion of Gram-negative bacteria resistant to all first-line antimicrobials increased from 7.0% (3/43) 
in the first period to 67.7% (315/465) in the last (p<0.001).  
 
For Gram-positives, penicillin resistance (including intermediate susceptibility) in S. pneumoniae did not 
increase significantly during the study period (p=0.210; Table 2). MRSA isolates increased from 0% 
(0/247) to 2.7% (6/224) which was not significant (p=0.09). Enterococcus spp. resistance to ampicillin 
increased from 11.1% (1/9) in the first period to 69.7% (69/99) in the last (p<0.001), which could be 
attributed to the seven-fold increase in E. faecium spp. isolated, concurrent with a relative decrease in E. 
faecalis over the same period.  
 
For Gram-negatives, excluding Salmonellae, an increase in resistance to ceftriaxone and gentamicin to 
over 60% during the study period was documented (Figure 3A). E. coli ceftriaxone resistance increased 
from 11.1% (4/36) in the first period to 28.5% (47/165) in the last (p<0.001), gentamicin resistance 
increased from 19.7% (48/244) in the first period to 32.7% (54/165) in the last (p<0.001), and ampicillin 
resistance remained unchanged and had a mean annual rate of 89.7% throughout the study period 
(p=0.466). For Klebsiella spp., ceftriaxone resistance rose from 21.1% (4/19) in the first period to 90.5% 
(286/316) in the last (overall increasing trend, p<0.001), whereas gentamicin resistance rose from 38.2% 
(68/178) in the first period to 90.7% (282/311) in the last (overall increasing trend, p<0.001). Resistance 
to ciprofloxacin for both pathogens was also observed to steadily increase during the two decades, from 
0% (0/113) in the first period to 26.0% (43/165) in the last (p<0.001) in E. coli, and 0% (0/73) to 34.5% 
(109/316) for Klebsiella spp (p<0.001). Resistance to all empiric first-line antimicrobials for E. coli was 
over 20% (Figure 3B) and there was an overall increasing trend in proportion of Klebsiella spp. resistant 
to all first-line antimicrobial regimens over time, from 5.9% (1/17) to 93.7% (133/142; p<0.001). Both S. 
Typhi and NTS had infrequent resistance to ceftriaxone (0/566 and 8/1,980) and ciprofloxacin (1/610 and 
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10/3,392) throughout all periods. We have not detected ESBL NTS BSI in children [18]. A similar trend 
in AMR profiles was also noted for young infants (Supplementary Table 3).  
 
Discussion 
Over the past two decades, overall, the incidence of BSI in hospitalized children at QECH, the largest 
teaching hospital in Malawi, has decreased. This includes NTS for which no vaccine was available during 
the study period, and for H. influenzae type b and S. pneumoniae for which vaccination programs were 
introduced (in 2002 and 2011, respectively). However, in the last ten years, the incidence of young infant 
BSI caused by S. Typhi and Klebsiella spp. in those under 5 has risen considerably. We have previously 
reported three epidemics of Salmonella which appear to have arisen through the acquisition of virulence 
and antimicrobial resistance determinants in the context of a susceptible population [19-22]. Gram-
positive pathogens are still largely susceptible to first-line antimicrobials, with the exception of 
Enterococcus spp. and E. faecium, which, as an emerging pathogen, needs ongoing surveillance. For 
Gram-negative BSI among children ≤5 years, the proportion of bacteria that are resistant to empiric first-
line antimicrobials is high, rising, and most marked among young infants. These findings reveal the 
growing problem of AMR in our setting and emphasize the need for robust antimicrobial stewardship 
programs and ongoing surveillance even when BSI overall appears to be declining. 
 
The rise in Gram-negative pathogens resistant to first-line antimicrobials, specifically Klebsiella spp., 
contrasts with earlier data from our institution where isolates had high susceptibility (78%) [23]. One 
reason for the rise in AMR could be attributed to a marked increase in the use of broad-spectrum 
antimicrobials in recent years [24] including among neonates. Klebsiella spp. isolates recovered within 
the first 3 days of birth accounted for 28.4% (84/295) of all pediatric Klebsiella spp. specimens in the last 
period, suggesting high rates of vertical transmission. The reasons for increase in rates of AMR Klebsiella 
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spp. are not certain, since there have been no changes in practice in the neonatal unit that we can identify. 
The increase may have been amplified by increased transmission capacity resulting in outbreaks in 
neonatal units [25, 26]. The high ESBL carriage in children <5 years [27] may have also contributed to 
horizontal transmission. Community-based surveillance of both disease and carriage is ongoing [28] to 
explore whether increasing rates of AMR may be related to strengthening of primary health care systems 
following the model of IMCI and earlier treatment with antimicrobials, and thereby limited to the hospital 
setting.  
 
Alternative antimicrobials for Gram-negatives in these settings could include use of amikacin, where 
resistance rates are much lower than gentamicin (6.3% compared to 66.0%, respectively); or 
ciprofloxacin, where resistance rates are already rising, and when used in children has to be weighed 
against the side effects of tendinopathy. The inclusion of meropenem on the Malawi national formulary in 
2015 and its availability in hospitals may be beneficial in the short term but increased use is likely to 
drive further AMR, similar to the increase in ESBL organisms seen following ceftriaxone use. This would 
be in a setting where there are limited diagnostic facilities and where antimicrobial stewardship initiatives 
are beset by scarce resources. 
 
Limitations to this study include that these are urban tertiary referral hospital-based data from a single 
site, and not national surveillance. However, such large-scale long-term routine surveillance data is rarely 
available in this setting at a national level. Hospital-based surveillance could have enriched for AMR, as 
susceptible BSI may have responded to empiric oral antibiotics in the community, and only the sickest 
children present to hospital. However, given the likely clinical severity of BSI, except for children with 
typhoid fever, and the absence of other pediatric inpatient facilities, this bias is unlikely to be substantial. 
We could not reliably differentiate community- from hospital-acquired bloodstream infections, which 
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could be particularly relevant to young infant BSI, where some neonates have prolonged stays and have 
follow-up blood cultures obtained prior to changes in antimicrobial regimens for presumed sepsis. 
Nosocomial BSI may have contributed to our relatively high recovery rate of 11.9% but many of the 
prominent pathogens are uncommonly associated with nosocomial transmission. As blood cultures are not 
routinely repeated if bacteria considered contaminants are isolated, we may have underestimated true 
pathogens; however, typical risk factors such as indwelling vascular devices or febrile neutropenia are 
extremely rare in this population and prematurity would not have accounted for a substantial proportion. 
ESBL screening was not introduced until 2003, and therefore ESBL-producing pathogens may have been 
circulating yet undetected before then. Changes made to breakpoints in subsequent BSAC versions would 
have led to wider use of ‘intermediate’ categories which, in our study, may have increased the number of 
Gram negatives regarded as resistant. In all pediatric BSI surveillance studies blood volumes for culture 
remain a challenge and therefore underestimates of pathogens such as S. pneumoniae and S. Typhi, 
particularly in infants are possible. Comprehensive clinical data was not available to evaluate the 
contribution of AMR to mortality, however, we have previously reported the mortality associated with 
specific pathogens [29-32].  
 
Our results raise significant concerns about the growing issue of AMR, and highlight the urgent need to 
review empiric antimicrobial regimens, implement and enforce infection control practices, and undertake 
pragmatic trials of antimicrobial stewardship. However, in many LMICs, without local data, it remains 
challenging to adapt the WHO IMCI guidelines to reflect local needs [5]. While awaiting the impact of 
international initiatives to expand access to high quality laboratory surveillance [33, 34] and the 
development of rapid diagnostics [35, 36], there should be considerable emphasis on expanded access to 
effective antimicrobials in the context of locally relevant antimicrobial stewardship programs. These 
should include the education of community and hospital-based healthcare providers on prescribing 
practices, improving the understanding of epidemiology of infections, when not to prescribe antibiotics, 
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the development of and adherence to guidelines on de-escalation and cessation of antimicrobial therapy, 
and greater emphasis on infection control practices. The development of pragmatic clinical trials to 
evaluate new antimicrobial strategies in young children should be a priority.  
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Tables and Figures: 
Table 1. Bloodstream infections in children ≤5 years at Queen Elizabeth Central Hospital, by isolate and 
period 
Table 2. Antimicrobial resistance profiles of selected bloodstream pathogens for children ≤5 years, by 
period 
 
Figure legend 
Figure 1. Negative binomial regression model estimated annual incidence rate per 1,000 person-years for 
children ≤5 years, for: A) All pathogenic organisms among those ≤5 years and ≤60 days; B) S. 
pneumoniae and S. aureus; C) Group A Strep and Group B Strep; D) S. Typhi and NTS; E) E. coli and 
Klebsiella spp.; F) Haemophilus spp. and other Gram-negatives. Scales have been adjusted for each 
organism.  
Figure 2. Proportion of culture-confirmed bloodstream pathogens resistant to empiric first-line 
antimicrobials* by period, for children ≤5 years and ≤60 days 
*First-line antimicrobials in Malawi are ampicillin/penicillin with gentamicin, or ceftriaxone. 
Figure 3. Proportion of non-Salmonella Gram-negative isolates with: A) Gentamicin- or ceftriaxone-
resistance, for children ≤5 years; B) E. coli and Klebsiella spp. resistance to empiric first-line 
antimicrobials*, for children ≤5 years 
*First-line antimicrobials in Malawi are ampicillin/penicillin with gentamicin, or ceftriaxone. 
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Table 1. Bloodstream infections in children ≤5 years at Queen Elizabeth Central Hospital, by 
isolate and period 
 Time period 
1998-2002 2003-2007 2008-2012 2013-2017 
N % N % N % N % 
Gram-positives         
Group A Strep 96 2.4 42 1.1 32 1.7 29 1.1 
Group B Strep 126 3.2 116 2.9 39 2.0 48 1.8 
Streptococcus 
pneumoniae 
405 10.2 423 10.7 166 8.6 49 1.9 
Staphylococcus aureus 247 6.2 283 7.1 185 9.6 253 9.7 
Other Streptococcus 
spp. 
197 5.0 244 6.1 193 10.0 222 8.5 
E. faecalis 26 0.7 63 1.6 38 2.0 30 1.1 
E. faecium 0 0 0 0 10 0.5 69 2.6 
All Enterococcus spp. 31 0.8 63 1.6 50 2.6 99 3.8 
Leuconostoc 0 0 1 0.03 0 0 0 0 
Gram-negatives         
Acinetobacter 
baumanii 
0 0 9 0.2 17 0.9 58 2.2 
All Acinetobacter spp. 86 2.2 101 2.5 35 1.8 59 2.3 
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Citrobacter spp. 37 0.9 33 0.8 6 0.3 7 0.3 
Enterobacter spp. 57 1.4 133 3.4 33 1.7 132 5.0 
Escherichia coli 247 6.2 282 7.1 163 8.5 165 6.3 
Haemophilus 
influenzae type b 
157 4.0 44 1.1 19 1.0 16 0.6 
All Haemophilus spp. 178 4.5 67 1.7 38 2.0 26 1.0 
Klebsiella pneumoniae 57 1.4 103 2.6 123 6.4 295 11.3 
All Klebsiella spp. 179 4.5 144 3.6 132 6.9 316 12.1 
Neisseria meningitidis 14 0.3 18 0.5 5 0.3 11 0.4 
N. gonorrhoea 0 0 0 0 1 0.05 6 0.3 
Proteus spp. 15 0.4 3 0.08 2 0.1 3 0.1 
Pseudomonas 
aeruginosa 
28 0.7 47 1.2 20 1.0 36 1.4 
All Pseudomonas spp. 38 1.0 55 1.4 33 1.7 49 1.9 
Salmonella Typhi 8 0.2 16 0.4 50 2.6 544 20.8 
NTS  1644 41.4 1505 37.9 532 27.7 303 11.6 
Serratia spp. 38 1.0 16 0.4 4 0.2 17 0.7 
Shigella spp. 3 0.08 4 0.1 4 0.2 6 0.2 
Vibrio spp. 0 0 0 0 2 0.1 0 0 
Yersinia spp. 2 0.05 0 0 2 0.1 0 0 
Other Gram-negatives
a
 301 7.6 412 10.4 203 10.6 253 9.7 
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Fungus         
Candida 5 0.1 1 0.03 4 0.2 7 0.3 
Cryptococcus 0 0 0 0 6 0.3 4 0.2 
Yeast species 0 0 0 0 0 0 3 0.1 
All pathogens
b
 3964 100 3970 100 1923 100 2614 100 
MRSA, methicillin-resistant Staph aureus; NTS, nontyphoidal Salmonella 
aIncludes Aeromonas spp., Agrobacter spp., Burkholderia spp., Cronobacter spp., Edwardsiella 
spp., Flavobacteria, Gram negative rods, Hafnia spp., Histophilus spp., Kluyvera spp., Moraxella 
spp., Morganella spp., Pantoea spp., Pasteurella spp., Raoultella spp., Sphingomonas spp., 
Stenotrophomonas spp., Xanthomonas spp.. 
bExcludes contaminants, including Aerococcus spp., alpha-hemolytic streptococci, Alcaligenes 
spp., Bacillus spp., Clostridium spp., coagulase-negative staphylococci, Corynebacteria, 
Diphtheroids, Gram positive rods, Rhizobium spp., Micrococcus spp., skin flora. 
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Figure 1 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy834/5113431 by U
niversity of Liverpool user on 11 O
ctober 2018
  29 
Figure 2 
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Figure 3 
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